Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 7/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 6/20 | 0.47 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA5A | P35218 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15747016 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10NR3C1FYN | |
| SCHEMBL1726948 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10NR3C1FYN | |
| SCHEMBL17724779 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10NR3C1FYN | |
| SCHEMBL20033571 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10NR3C1FYN | |
| SCHEMBL17192718 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10NR3C1FYN | |
| SCHEMBL1687338 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10NR3C1FYN | |
| SCHEMBL18105805 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10NR3C1FYN | |
| SCHEMBL15040789 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10NR3C1FYN | |
| SCHEMBL8515524 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10NR3C1FYN | |
| SCHEMBL19304535 | 1.00 | CYP2D6 (0.59) | CYP2D6THRBHSD17B10NR3C1FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036818-A | Synthesis of 3-fucosyllactose | 天津科技大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20250346622-A1 | NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-11-13 | — | — | US | disclosed |
| EP-4424717-A1 | NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE | Daiichi Sankyo Company, Limited (JP) | 2024-09-04 | — | — | EP | disclosed |
| CN-118302451-A | Novel oligosaccharide, intermediate for producing the oligosaccharide, and process for producing the same | 第一三共株式会社 | 2024-07-05 | — | — | CN | disclosed |
| WO-2024127332-A1 | CYTOTOXIC COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024127332-A1 | CYTOTOXIC COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-06-20 | — | — | WO | disclosed |
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2023-09-12 | — | — | US | disclosed |
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | INTOCELL, INC. (KR) | 2023-09-12 | — | — | US | disclosed |
| WO-2023074843-A1 | NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE | 第一三共株式会社 | 2023-05-04 | — | — | WO | disclosed |
| US-11365263-B2 | Bifunctional cytotoxic agents containing the CTI pharmacophore | PFIZER INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20040033962-A1 | Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo[3,2-e]indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]quinoline derivatives for use in selective cancer therapy | TIETZE, LUTZ F. (DE) | 2004-02-19 | — | — | US | disclosed |
| EP-1280771-A2 | NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO 3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY | Tietze, Lutz F., Prof. Dr. (DE) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001083448-A2 | NOVEL PRODRUGS VON 6-HYDROXY-2,3-DIHYDRO-1H-INDOLES, 5-HYDROXY-1,2-DIHYDRO-3H-PYRROLO[3,2-E]INDOLES AND 5-HYDROXY-1,2-DIHYDRO-3H-BENZO(E)INDOLES AS WELL AS OF 6-HYDROXY-1,2,3,4-TETRAHYDRO-BENZO[F]QUINOLINE DERIVATIVES FOR USE IN SELECTIVE CANCER THERAPY | TIETZE LUTZ F (DE) | 2001-11-08 | — | — | WO | disclosed |
| WO-1997018222-A9 | NOVEL OLIGOSACCHARIDE GLYCOSIDES HAVING MAMMALIAN IMMUNOSUPPRESSIVE AND TOLEROGENIC PROPERTIES | GLYCOMED INC (US) | 1999-07-01 | — | — | WO | disclosed |
| US-5874411-A | ANTIINFLAMMATORY | GLYCOMED INCORPORATED (US) | 1999-02-23 | — | — | US | disclosed |
| WO-1997018222-A2 | NOVEL OLIGOSACCHARIDE GLYCOSIDES HAVING MAMMALIAN IMMUNOSUPPRESSIVE AND TOLEROGENIC PROPERTIES | GLYCOMED, INC. (US) | 1997-05-22 | — | — | WO | disclosed |
| US-5565433-A | ADMINISTERING IN TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996016071-A1 | PROCESSES FOR THE SYNTHESIS OF 3'-SUBSTITUTED LEWISx COMPOUNDS | GLYCOMED, INC. (US) | 1996-05-30 | — | — | WO | disclosed |
| EP-0671406-A2 | Sulfated beta-glycolipid derivatives as cell adhesion inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-09-13 | — | — | EP | disclosed |
| EP-0578026-A1 | Polymeric Lewis X saccharides and process for their preparation | MERCK PATENT GmbH (DE) | 1994-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365263-B2 | Bifunctional cytotoxic agents containing the CTI pharmacophore | CCNI, TTI1, TTI2 | CYP2D6 1383/4885THRB 1447/4885HSD17B10 3289/4885 |
| US-20250346622-A1 | NOVEL OLIGOSACCHARIDE, MANUFACTURING INTERMEDIATE FOR NOVEL OLIGOSACCHARIDE, AND METHOD FOR MANUFACTURING THESE | FUT6, FUT5, ST3GAL3 | CYP2D6 629/4885THRB 3301/4885HSD17B10 549/4885 |
| US-11753431-B2 | Compounds comprising cleavable linker and uses thereof | VIP, ANTXR2, TNFRSF9 | CYP2D6 3753/4885THRB 1395/4885HSD17B10 4748/4885 |
| US-20040033962-A1 | Novel prodrugs von 6-hydroxy-2,3-dihydro-1h-indoles, 5-hydroxy-1,2-dihydro-3h-pyrrolo[3,2-e]indoles and 5-hydroxy-1,2-dihydro-3h-benzo(e)indoles as well as of 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]quinoline derivatives for use in selective cancer therapy | DHPS, DERA, DUT | CYP2D6 63/4885THRB 3134/4885HSD17B10 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.